BK Virus Nephropathy After Chimeric Antigen Receptor (CAR)-T Cell Therapy for Diffuse Large B-Cell Lymphoma in a Kidney Transplant Recipient (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO1145; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 26-year-old man with ESKD underwent kidney transplant 8 years ago, with basiliximab induction and maintained on tacrolimus/ and mycophenolic acid with stable renal function and undetectable BK and EBV PCRs...Mycophenolic acid was replaced with prednisone, and he received 6 cycles of R-CHOP for advanced-stage disease...He then underwent CAR T-cell therapy following lymphodepletion with fludarabine and cyclophosphamide...Discussion BK viremia and BKVN may develop after CAR T-cell therapy in KTRs despite previously negative BK PCR throughout conventional chemotherapy. Careful post-CAR T monitoring for BK virus should be considered in this population."
Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Renal Disease • Transplantation
|
|
Walaa Dabbas; Hannah Dzielawa; Kathy Marie De La Torre; Carlos Galvez; Benito Valdepenas; Ruchi Harshadrai Naik; Ignatius Yun-Sang Tang
|